ANRO
Alto Neuroscience Inc.

1,103
Mkt Cap
$685.87M
Volume
423,583.00
52W High
$25.17
52W Low
$1.60
PE Ratio
-9.56
ANRO Fundamentals
Price
$21.47
Prev Close
$22.04
Open
$21.25
50D MA
$18.43
Beta
1.66
Avg. Volume
227,498.30
EPS (Annual)
-$2.19
P/B
4.53
Rev/Employee
$0.00
$361.04
Loading...
Loading...
News
all
press releases
Alto Neuroscience (NYSE:ANRO) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen lowered shares of Alto Neuroscience from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·20h ago
News Placeholder
More News
News Placeholder
HC Wainwright Issues Negative Estimate for ANRO Earnings
Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Equities research analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for Alto Neuroscience in a research note issued to investors on Wednesday, March 18th. HC Wainwright analyst P. Trucchio now forecasts that the company w...
MarketBeat·2d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, Robert W. Baird Analyst Says
Robert W. Baird raised their target price on Alto Neuroscience from $22.00 to $41.00 and gave the company an "outperform" rating in a research report on Wednesday...
MarketBeat·4d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6% - Time to Sell?
Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6% - Time to Sell...
MarketBeat·4d ago
News Placeholder
Chardan Capital Reiterates "Buy" Rating for Alto Neuroscience (NYSE:ANRO)
Chardan Capital reissued a "buy" rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research note on Tuesday...
MarketBeat·5d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Price Target Raised to $22.00
Wedbush upped their price objective on shares of Alto Neuroscience from $13.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday...
MarketBeat·5d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Sets New 1-Year High - Here's Why
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High - Still a Buy...
MarketBeat·5d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Estimates By $0.11 EPS
Alto Neuroscience (NYSE:ANRO - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.56...
MarketBeat·6d ago
News Placeholder
Alto Neuroscience Announces $120 Million Private Placement Financing
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it...
Business Wire·6d ago
News Placeholder
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported...
Business Wire·6d ago
<
1
2
...
>

Latest ANRO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.